Allergan Presents Data at the 2015 American Academy of Ophthalmology (AAO) Annual Meeting in Las Vegas

DUBLIN, Nov. 12, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN), today announced that its data will be featured  as oral presentations during the 2015 American Academy of Ophthalmology (AAO) Annual Meeting in Las Vegas, Nevada, November 13-17, 2015.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

The scheduled times (noted in local Pacific Time) of the five Allergan presentations, Sand Expo/ Venetian Hotel room locations, presentation titles, and lead authors are as follows: 

• 2015 Retina Subspecialty Day, "Long-Term Response to Anti-VEGF Therapy for DME Can be Predicted After 3 Injections – An Analysis of Protocol I Data"
  • Presenter: Pravin U. Dugel, MD
  • Date and Time: Friday, November 13, 11:35 - 11:41AM
  • Room: Palazzo Ballroom
  • Topic: Retina
    
• "Bimatoprost Sustained-Release Implants for Glaucoma Therapy: Interim Results From a 24-Month Phase 1/2 Clinical Trial"
  • Presenter: Richard Lewis, MD
  • Date and Time: Sunday, November 15, 12:30 - 2:00PM
  • Room: Hall G
  • Topic: Glaucoma
    
• "Poor Medication Adherence Increases Visual Field Progression in Glaucoma"
  • Presenter: Donald S. Fong, MD
  • Date and Time: Monday, November 16, 12:30 - 2:00PM
  • Room: Hall G
  • Topic: Glaucoma
    
• "XEN-45 Gel Stent for the Treatment of Uveitic Glaucoma"
  • Presenter: Chelvin Sng, MBBChir, FRCSEd
  • Date and Time: Monday, November 16, 12:30 - 2:00PM
  • Room: Hall G
  • Topic: Glaucoma
    
• "A Novel Ab Interno Gelatin Stent for Reducing Elevated IOP in Open-Angle Glaucoma: One-Year Follow-up Results"
  • Presenter: Rohit Varma, MD
  • Date and Time: Tuesday, November 17, 9:42 - 9:49AM
  • Room: Venetian Ballroom D
  • Topic: Glaucoma

About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharmacy.  Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenteritis, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, health care providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergen's website at www.Allergan.com.

Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergen's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergen's current expectations depending upon a number of factors affecting Allergen's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergen's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergen's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (such periodic public filings having been filed under the "Acta vis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:
Investors:
Lisa De Francesco                                       
(862) 261-7152

Media:
Mark Murmur
(862) 261-7558

SOURCE Allergan plc

Related Links

http://www.allergan.com